AGIOS PHARMACEUTICALS, INC.·4

Jun 23, 5:23 PM ET

Foster-Cheek Kaye I 4

4 · AGIOS PHARMACEUTICALS, INC. · Filed Jun 23, 2026

Research Summary

AI-generated summary of this filing

Updated

AGIOS (AGIO) Director Kaye Foster‑Cheek Exercises Derivatives, Receives Awards

What Happened Kaye Foster‑Cheek (Director) reported several derivative and award transactions dated June 18, 2026. She (1) exercised/converted 2,816 derivative units (reported as M) and a corresponding 2,816-share derivative disposition, and (2) acquired awards/stock units totaling 2,927 shares (vested/settled) and 14,950 shares (new grant/award). All transactions show an acquisition price of $0. Total reported share counts from these lines sum to 20,509 shares/units (values reported as $0).

Key Details

  • Transaction date: June 18, 2026; filing date: June 23, 2026 (period of report 2026-06-18).
  • Reported prices and values: $0.00 per share for all items; total reported cash value $0.
  • Specific line items:
    • Exercise/conversion (M): 2,816 shares acquired; 2,816 shares disposed (derivative).
    • Grant/award (A): 2,927 shares acquired (vested RSUs from 6/18/2025).
    • Grant/award (A): 14,950 shares acquired (new awards/options granted 6/18/2026).
  • Shares owned after these transactions: not disclosed in the provided filing excerpt.
  • Relevant footnotes:
    • F1: Each restricted stock unit (RSU) represents a contingent right to one share.
    • F2: The 2,927 RSUs were granted 6/18/2025 and vest in full 6/18/2026; vested shares to be delivered within three business days after vesting.
    • F3: The 14,950 stock units were granted 6/18/2026 and vest in full 6/18/2027.
    • F4: Options were granted 6/18/2026 and vest 100% on 6/18/2027.
  • No 10b5‑1 plan, tax‑withholding details, or late‑filing flag were provided in the excerpt.

Context

  • These transactions are award/derivative related (vesting/settlement and new grants), not open‑market purchases or sales; such award activity typically reflects equity compensation rather than a market sentiment trade.
  • The exercise/conversion plus immediate disposition of 2,816 derivative shares likely reflects a settlement/processing event (e.g., conversion and transfer/withholding) as reported; the filing does not specify a cash sale.
  • For retail investors: awards and option grants increase potential future share supply when they vest/exercise; they are compensation events and should be interpreted differently than an insider buying or selling shares in the open market.

Insider Transaction Report

Form 4
Period: 2026-06-18
Transactions
  • Exercise/Conversion

    Common stock

    2026-06-18+2,81610,284 total
  • Exercise/Conversion

    Restricted stock units

    [F1][F2]
    2026-06-182,8160 total
    Common stock (2,816 underlying)
  • Award

    Restricted stock units

    [F1][F3]
    2026-06-18+2,9272,927 total
    Common stock (2,927 underlying)
  • Award

    Stock options (right to buy)

    [F4]
    2026-06-18+14,95014,950 total
    Exercise: $34.16Exp: 2036-06-18Common stock (14,950 underlying)
Holdings
  • Common stock

    (indirect: By Trust)
    2,200
Footnotes (4)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  • [F2]The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
  • [F3]The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
  • [F4]These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
Signature
/s/ William Cook, as Attorney-in-fact for Kaye Foster|2026-06-23

Documents

1 file
  • 4
    wk-form4_1782249832.xmlPrimary

    FORM 4